WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 329831
CAS#: 51012-33-0 (HCl)
Description: Tiapride is a drug that selectively blocks D2 and D3 dopamine receptors in the brain. It is used to treat a variety of neurological and psychiatric disorders including dyskinesia, alcohol withdrawal syndrome, negative symptoms of psychosis, and agitation and aggression in the elderly. Tiapride is a dopamine D2 and D3 receptor antagonist. It is more selective than other neuroleptic drugs such as haloperidol and risperidone, which not only target four of the five known dopamine receptor subtypes (D1-4), but also block serotonin (5-HT2A, 2C), α1- and α2-adrenergic, and histamine H1 receptors.
MedKoo Cat#: 329831
Name: Tiapride HCl
CAS#: 51012-33-0 (HCl)
Chemical Formula: C15H25ClN2O4S
Exact Mass:
Molecular Weight: 364.885
Elemental Analysis: C, 49.38; H, 6.91; Cl, 9.72; N, 7.68; O, 17.54; S, 8.79
Related CAS #: 51012-32-9 (free base) 51012-33-0 (HCl)
Synonym: Tiapride HCl, Tiapride Hydrochloride;
IUPAC/Chemical Name: N-(2-(Diethylamino)ethyl)-2-methoxy-5-(methylsulphonyl)benzamide monohydrochloride
InChi Key: OTFDPNXIVHBTKW-UHFFFAOYSA-N
InChi Code: InChI=1S/C15H24N2O4S.ClH/c1-5-17(6-2)10-9-16-15(18)13-11-12(22(4,19)20)7-8-14(13)21-3;/h7-8,11H,5-6,9-10H2,1-4H3,(H,16,18);1H
SMILES Code: O=C(NCCN(CC)CC)C1=CC(S(=O)(C)=O)=CC=C1OC.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 364.885 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Nagamine T. Severe Hypoglycemia Associated with Tiapride in an Elderly Patient with Diabetes and Psychosis. Innov Clin Neurosci. 2017 Feb 1;14(1-2):12-13. eCollection 2017 Jan-Feb. PubMed PMID: 28409061; PubMed Central PMCID: PMC5373790.
2: Trawiński J, Skibiński R. Photolytic and photocatalytic degradation of the antipsychotic agent tiapride: Kinetics, transformation pathways and computational toxicity assessment. J Hazard Mater. 2017 Jan 5;321:841-858. doi: 10.1016/j.jhazmat.2016.10.001. Epub 2016 Oct 6. PubMed PMID: 27745957.
3: Yuan Y, Li LH, Huang YJ, Lei LF. Tiapride is more effective and causes fewer adverse effects than risperidone in the treatment of senile dementia. Eur Rev Med Pharmacol Sci. 2016 Jul;20(14):3119-22. PubMed PMID: 27460743.
4: Lissek S, Glaubitz B, Wolf OT, Tegenthoff M. The DA antagonist tiapride impairs context-related extinction learning in a novel context without affecting renewal. Front Behav Neurosci. 2015 Sep 3;9:238. doi: 10.3389/fnbeh.2015.00238. eCollection 2015. PubMed PMID: 26388752; PubMed Central PMCID: PMC4558976.
5: Hurtado MM, García R, Puerto A. Tiapride impairs the aversive effect of electrical stimulation of the parabrachial complex in a conditioned place task. Acta Neurobiol Exp (Wars). 2014;74(3):307-16. PubMed PMID: 25231850.
6: Lissek S, Vallana GS, Schlaffke L, Lenz M, Dinse HR, Tegenthoff M. Opposing effects of dopamine antagonism in a motor sequence task-tiapride increases cortical excitability and impairs motor learning. Front Behav Neurosci. 2014 Jun 19;8:201. doi: 10.3389/fnbeh.2014.00201. eCollection 2014. PubMed PMID: 24994972; PubMed Central PMCID: PMC4063238.
7: Nozaki I, Furukawa Y, Kato-Motozaki Y, Ikeda T, Tagami A, Takahashi K, Ishida C, Komai K. Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and tiapride in a Japanese patient with Huntington's disease at the terminal stage of recurrent breast cancer. Intern Med. 2014;53(11):1201-4. Epub 2014 Jun 1. PubMed PMID: 24881749.
8: Karia S, Shah N, De Sousa A, Sonavane S. Tiapride for the treatment of auditory hallucinations in schizophrenia. Indian J Psychol Med. 2013 Oct;35(4):397-9. doi: 10.4103/0253-7176.122238. PubMed PMID: 24379503; PubMed Central PMCID: PMC3868094.
9: Mendoza-Otero F, Gómez Vidal JA, Vila-Clérigues N, Muros-Ortega M, García-Molina O, De La Rubia Nieto A. [Assessment of a Tiapride solution for its administration through continuous intravenous perfusion]. Farm Hosp. 2013 Jan-Feb;37(1):10-4. doi: 10.7399/FH.2013.37.1.53. Spanish. PubMed PMID: 23461495.
10: Nobilis M, Vybíralová Z, Szotáková B, Sládková K, Kuneš M, Svoboda Z. High-performance liquid chromatographic determination of tiapride and its phase I metabolite in blood plasma using tandem UV photodiode-array and fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Dec 15;879(32):3845-52. doi: 10.1016/j.jchromb.2011.10.032. Epub 2011 Nov 3. PubMed PMID: 22100559.
11: Mediavilla C, Mahía J, Bernal A, Puerto A. The D2/D3-receptor antagonist tiapride impairs concurrent but not sequential taste aversion learning. Brain Res Bull. 2012 Feb 10;87(2-3):346-9. doi: 10.1016/j.brainresbull.2011.10.022. Epub 2011 Nov 9. PubMed PMID: 22085742.
12: Müller CA, Schäfer M, Banas R, Heimann HM, Volkmar K, Förg A, Heinz A, Hein J. A combination of levetiracetam and tiapride for outpatient alcohol detoxification: a case series. J Addict Med. 2011 Jun;5(2):153-6. doi: 10.1097/ADM.0b013e3181ec5f81. PubMed PMID: 21769061.
13: Zayed SI. Differential pulse anodic voltammetric determination of tiapride hydrochloride in pharmaceutical preparation and human urine using carbon paste electrodes. Anal Sci. 2011;27(5):535. PubMed PMID: 21558662.
14: Jo SH, Lee SY. Response of i(kr) and HERG currents to the antipsychotics tiapride and sulpiride. Korean J Physiol Pharmacol. 2010 Oct;14(5):305-10. doi: 10.4196/kjpp.2010.14.5.305. Epub 2010 Oct 31. PubMed PMID: 21165329; PubMed Central PMCID: PMC2997416.
15: Liu YY, Chen YH, Chen H, Liu ZS. [A control study of aripiprazole and tiapride treatment for tic disorders in children]. Zhongguo Dang Dai Er Ke Za Zhi. 2010 Jun;12(6):421-4. Chinese. PubMed PMID: 20540847.
16: Martinotti G, di Nicola M, Frustaci A, Romanelli R, Tedeschi D, Guglielmo R, Guerriero L, Bruschi A, De Filippis R, Pozzi G, Di Giannantonio M, Bria P, Janiri L. Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi-centre, randomized, single-blind comparison trial. Addiction. 2010 Feb;105(2):288-99. doi: 10.1111/j.1360-0443.2009.02792.x. PubMed PMID: 20078487.
17: Zhang H, Cheng S. [Tiapride with the horn of saiga tatarica in the treatment of hemifacial spasm]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Aug;23(16):749-51. Chinese. PubMed PMID: 20041610.
18: Canal M, Desanti CR, Santoni JP. A new oral formulation of tiapride (drops): pharmacokinetic profile and therapeutic applications. Clin Drug Investig. 1998;15(5):455-60. PubMed PMID: 18370501.
19: Metwally FH, Abdelkawy M, Abdelwahab NS. Stability-indicating methods for determination of tiapride in pure form, pharmaceutical preparation, and human plasma. J AOAC Int. 2007 Nov-Dec;90(6):1554-65. PubMed PMID: 18193732.
20: Metwally FH. Membrane sensors for the selective determination of tiapride in presence of its degradation products. Yakugaku Zasshi. 2007 Aug;127(8):1267-73. PubMed PMID: 17666880.
A derivative of benzamide, tiapride is chemically and functionally similar to other benzamide antipsychotics such as sulpiride and amisulpride known for their dopamine antagonist effects.
